Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity

被引:146
作者
Bijker, Else M. [1 ]
Bastiaens, Guido J. H. [1 ]
Teirlinck, Anne C. [1 ]
van Gemert, Geert-Jan [1 ]
Graumans, Wouter [1 ]
van de Vegte-Bolmer, Marga [1 ]
Siebelink-Stoter, Rianne [1 ]
Arens, Theo [1 ]
Teelen, Karina [1 ]
Nahrendorf, Wiebke [3 ]
Remarque, Edmond J. [4 ]
Roeffen, Will [1 ]
Jansens, Annemieke [1 ]
Zimmerman, Dunja [1 ]
Vos, Martijn [1 ]
van Schaijk, Ben C. L. [1 ]
Wiersma, Jorien [1 ]
van der Ven, Andre J. A. M. [2 ]
de Mast, Quirijn [2 ]
van Lieshout, Lisette [5 ]
Verweij, Jaco J. [5 ]
Hermsen, Cornelus C. [1 ]
Scholzen, Anja [1 ]
Sauerwein, Robert W. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands
[3] Natl Inst Med Res, Med Res Council, Div Parasitol, London NW7 1AA, England
[4] Biomed Primate Res Ctr, NL-2280 GH Rijswijk, Netherlands
[5] Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands
关键词
CD8+ T-CELLS; PLASMODIUM-FALCIPARUM; BLOOD-STAGE; ACQUIRED-IMMUNITY; CLINICAL IMMUNITY; GAMMA-INTERFERON; GROWTH-RATES; NK CELLS; CHALLENGE; VACCINATION;
D O I
10.1073/pnas.1220360110
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Volunteers immunized under chloroquine chemoprophylaxis with Plasmodium falciparum sporozoites (CPS) develop complete, long-lasting protection against homologous sporozoite challenge. Chloroquine affects neither sporozoites nor liver-stages, but kills only asexual forms in erythrocytes once released from the liver into the circulation. Consequently, CPS immunization exposes the host to antigens from both preerythrocytic and blood stages, and induced immunity might target either of these stages. We therefore explored the life cycle stage specificity of CPS-induced protection. Twenty-five malaria-nave volunteers were enrolled in a clinical trial, 15 of whom received CPS immunization. Five immunized subjects and five controls received a sporozoite challenge by mosquito bites, whereas nine immunized and five control subjects received an i.v. challenge with P. falciparum-infected erythrocytes. The latter approach completely bypasses preerythrocytic stages, enabling a direct comparison of protection against either life cycle stage. CPS-immunized subjects (13 of 14) developed anticircumsporozoite antibodies, whereas only one volunteer generated minimal titers against typical blood-stage antigens. IgG from CPS-immunized volunteers did not inhibit asexual blood-stage growth in vitro. All CPS-immunized subjects (5 of 5) were protected against sporozoite challenge. In contrast, nine of nine CPS-immunized subjects developed parasitemia after blood-stage challenge, with identical prepatent periods and blood-stage multiplication rates compared with controls. Intravenously challenged CPS-immunized subjects showed earlier fever and increased plasma concentrations of inflammatory markers D-dimer, IFN-gamma, and monokine induced by IFN-gamma than i.v. challenged controls. The complete lack of protection against blood-stage challenge indicates that CPS-induced protection is mediated by immunity against preerythrocytic stages. However, evidence is presented for immune recognition of P. falciparum-infected erythrocytes, suggesting memory responses unable to generate functional immunity.
引用
收藏
页码:7862 / 7867
页数:6
相关论文
共 37 条
  • [1] Microscopic and sub-microscopic Plasmodium falciparum infection, but not inflammation caused by infection, is associated with low birth weight
    Adegnika, Ayola A.
    Verweij, Jaco J.
    Agnandji, Selidji T.
    Chai, Sanders K.
    Breitling, Lutz Ph.
    Ramharter, Michael
    Frolich, Marijke
    Issifou, Saadou
    Kremsner, Peter G.
    Yazdanbakhsh, Maria
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2006, 75 (05) : 798 - 803
  • [2] Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes
    Artavanis-Tsakonas, K
    Eleme, K
    McQueen, KL
    Cheng, NW
    Parham, P
    Davis, DM
    Riley, EM
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (10) : 5396 - 5405
  • [3] Onset of clinical immunity to Plasmodium falciparum among Java']Javanese migrants to Indonesian Papua
    Baird, JK
    Krisin
    Barcus, MJ
    Elyazar, IRF
    Bangs, MJ
    Maguire, JD
    Fryauff, DJ
    Richie, TL
    Sekartuti
    Kalalo, W
    [J]. ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 2003, 97 (06): : 557 - 564
  • [4] Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment
    Belnoue, E
    Costa, FTM
    Frankenberg, T
    Vigário, AM
    Voza, T
    Leroy, N
    Rodrigues, MM
    Landau, I
    Snounou, G
    Rénia, L
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (04) : 2487 - 2495
  • [5] Whole parasite vaccination approaches for prevention of malaria infection
    Butler, Noah S.
    Vaughan, Ashley M.
    Harty, John T.
    Kappe, Stefan H. I.
    [J]. TRENDS IN IMMUNOLOGY, 2012, 33 (05) : 247 - 254
  • [6] Measurement of Plasmodium falciparum growth rates in vivo: A test of malaria vaccines
    Cheng, Q
    Lawrence, G
    Reed, C
    Stowers, A
    RanfordCartwright, L
    Creasey, A
    Carter, R
    Saul, A
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1997, 57 (04) : 495 - 500
  • [7] CLYDE DF, 1990, B WORLD HEALTH ORGAN, V68, P9
  • [8] GAMMA-GLOBULIN AND ACQUIRED IMMUNITY TO HUMAN MALARIA
    COHEN, S
    CARRINGTON, S
    MCGREGOR, IA
    [J]. NATURE, 1961, 192 (480) : 733 - &
  • [9] A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum:: Development of parasitologic and clinical immunity following secondary
    Collins, WE
    Jeffery, GM
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 61 (01) : 20 - 35
  • [10] Acquired Immunity to Malaria
    Doolan, Denise L.
    Dobano, Carlota
    Baird, J. Kevin
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2009, 22 (01) : 13 - 36